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Chaninun Ketkaew*, Niyada Kiatying-Angsulee among prescribers, high number of adverse drug reactions, sign of treatment failures, excessive number of nonformulary drugs used and use of high cost drugs where less expensive alternatives exist. The DUE composed of 4 process as, first define appropriate drug use by establishing approved criteria, second audit criteria against what is being prescribed, third provide feedback to prescribers on all identified problems, and finally monitor to see if criteria are followed and prescribing improved (Health, 2007) . Many studies focused on evaluated use of cancer drug especially targeted therapy drugs and chemotherapy drugs because of its expensive and high risk in adverse drug reaction (Delpeuch, Leveque, Rob, & Bergerat, 2011; Gulam Muhammad Khan, 2013; Joerger et al., 2014; Krzyzanowska, 2013; Lerose, Musto, Aieta, Papa, & Tartarone, 2012; Pasqualetti et al., 2012; Siddiqua A., 2014; Wang et al., 2013) . Few studies focused on evaluation of endocrine therapy in breast cancer, for example, Kahan N.R. et al. showed 5.8% off-label use of Tamoxifen in Isael (Kahan, Waitman, Blackman, & Vardy, 2010) . This study aimed to describe the appropriate use of Letrozole referred to the treatment guideline by Thai National Formulary (TNF) version 2010 (National List of Essential Medicine Development Subcomittee, 2010; National List of Essential Medicines, 2009) and describe the pattern of use between three health benefit schemes. Letrozole is endocrine therapy drug for breast cancer as inhibit hormone action and stop tumor cell growth (Barnadas et al., 2011; Cohen, Johnson, Justice, & Pazdur, 2011; Lee, Armstrong, & Wardley, 2012; Shaw & Ellis, 2002) . It was launched in Thailand more than ten years ago but not listed in the National Essential Drug List until 2010. Because of expensive drug, sale price of original drug was 256 Baht/tablet in 2009 (7 -8 US$/tablet, 1 US$=35 Baht) and major health schemes was not covered. In 2010, The Ministry of Public Health announced Letrozole as compulsory licensed drugs that was centrally procured and distributed by The Government Pharmaceutical Organization (GPO). After that Letrozole was listed in the National Essential Drug List of Thailand 2010 in J-2 category and its sale price was only 7 Baht/ tablet (0.20 US$/tablet). To ensure that breast cancer patients can appropriately access to Letrozole, DUE process should be performed.
Materials and Methods
Retrospective research was performed at seven regional cancer hospitals in Chonburi, Lopburi, Lumpang, Pathumthani, Ubonrachathani, Udonthani and Suratthani. Regional cancer hospitals were referral hospital for cancer. All hospitals should be met four system criteria.
1) The hospitals were tertiary care in cancer treatment due to the National Health Security Organization (NHSO) guideline.
2) The hospital must be registered in NHSO hospital lists
3) The specialists of each hospital must be registered as Letrozole's prescriber 4) The patients of each hospital must be registered as breast cancer patients All prescriptions of Letrozole between January -June 2010 were collected from prescription paper and pharmacy dispensing database. The information obtained from prescriptions were prescriptions' date, hospital number (HN), ages, health benefit schemes, specialty of physician, dose and administration, amount of Letrozole tablet and calcium supplement prescribing data. Those data were recorded in data collection form by trained pharmacists. The medical record of patients were reviewed for the clinical characteristic and compare with DUE criteria.
The establishing approved criterion of this study was 
Results
Demographic data of the prescription of Letrozole has been shown in Table 1 . There were 681 prescriptions of Letrozole for 254 patients. The average age of patients was 58.6 ± 10.0 years old. Patients were in Universal Coverage Scheme (UCS) (77.7%), Civil Servant of Medication Benefit Scheme (CSMBS) (18.5%) and Social Security Scheme (SSS) (8.7%). 10.6% were prescribed of Letrozole for the first time. Letrozole were prescribed by oncologists (82.8%), radiologists (13.7%) and surgeons (3.5%). The average amount of tablets per prescription was 58 ± 10 tablets. 100.0% of prescriptions were appropriately dose prescribed. 19.4% of Letrozole prescriptions were prescribed with calcium supplement.
The clinical data of breast cancer patients obtained from medical record has been shown in 45 from 681 prescriptions were excluded from this study because lack of clinical data such as hormone receptor status and/or menstrual status. 636 prescriptions of Letrozole were analyzed with 1 -5 DUE criteria respectively.
Criteria 1: Letrozole must be rationally prescribed in ER (+) and/or PR (+) (ER(+)/PR(+), ER(+)/PR(-) and ER(-)/PR(+)). Mechanism of Letrozole is inhibiting of breast tumor growth by inhibiting biosynthesis of hormone, so high density of hormone receptor show better efficacy. 6 from 636 prescriptions (0.9%) were not appropriately prescribed for ER and/or PR positive. 630 appropriated prescriptions were continually evaluated in next criteria.
Criteria 2: Letrozole must be rationally prescribed in post-menopausal breast cancer patients. Post-menopausal can be identified by 3 criteria: 1) Age more than 60 years old, 2) under ovarian ablation 3) Post-menopausal occurred for 1 year before breast cancer diagnosed and confirm by FSH and LH. Pre-menopausal patients show estrogen effect that stimulates tumor cell growth. There were 31 prescriptions (4.9%) of Letrozole prescribed in pre-menopausal. Those were evaluated as inappropriate use. 599 prescriptions were continually evaluated in next criteria.
Criteria 3: Approve indication of Letrozole was in advance breast cancer and adjuvant therapy in early stage breast cancer. All 599 prescriptions were appropriated indication.
Criteria 4: The appropriate dose of Letrozole was fixed as 2.5 mg tablet orally once a day. All 599 prescriptions were prescribed in appropriate dose.
Criteria 5: The appropriate duration of letrozole were defined in line with the indication as follow -Advance breast cancer: Letrozole can be prescribed continually until the disease progress. -Adjuvant therapy in early stage breast cancer: Letrozole can be prescribed before and after Tamoxifen as switching therapy but not more than 2 years.
For these criteria, 49 prescriptions (7.7%) were inappropriate duration of prescribed.
Finally there were 86 (13.52%) inappropriate prescriptions of Letrozole, and 550 (86.48%) appropriated prescriptions from totally 636 prescriptions.
To describe appropriate use in different health benefit schemes, the study showed similarly percentage of appropriate prescriptions. The prescription of Letrozole in CSMBS was appropriated as 85.7%, SSS was 86.4% and UCS was 86.7%. A chi-square test of independence examined the relationship between health benefit scheme (CSMBS, SSS and UCS) and appropriate use of Letrozole (Appropriate, Inappropriate). The relationship between these variables was not statistically significant, χ 2 (2, N=636)=0.081, p>0.05.
Discussion
This study show inappropriate use of Letrozole in 3 criteria including inappropriate duration (7.7%), inappropriate menopausal status (4.9%) and inappropriate hormone receptor (0.9%). TNF guideline 2010 indicates the total duration of endocrine therapy in early stage breast cancer as sequential treatment (start with Tamoxifen for 3 years then followed by Letrozole for 2 years /strat with Letrozole for 2 years then followed by Tamoxifen for 3 years) not more than 5 years. That was consistent with the previous studies included BIG 1-98 trials and others (Gelmon, 2007; Goss, 2007; Regan et al., 2011) . However prescribing Tamoxifen for 5 years in early breast cancer patients still practically, those patients always continue with Letrozole for 2 years. That caused total duration of endocrine therapy was more than 5 years and be evaluated as inappropriate use. Other reason for inappropriate duration of Letrozole related to the National List of Essential Drug that already contained Tamoxifen for a long time and it always be drug of choices, although early study that show the significant benefit of starting Letrozole in early breast cancer because of its good efficacy and less adverse reaction (Bundred, 2006; Scott & Keam, 2006) . Furthermore, some patients in this study started endocrine treatment before TNF guideline was established, by previous treatment may be based on the previous guideline and was not consistence with the TNF guideline. Some patients may be first prescribed other aromatase inhibitor (Nabholtz et al., 2009 ) (Exemestane or Anastrozole) before shifted to Letrozole. The total duration aromatase inhibitor were accumulated, however the study in Thailand showed not significant respond after aromatase inhibitor was shifted (Aphinives, Vachirodom, Thanapaisal, Rangsrikajee, & Somintara, 2014) . Letrozole should be prescribed only in hormone receptor positive and postmenopause (Keating, 2009; Mann et al., 2005; Scott & Keam, 2006; Yadav, Sharma, Patel, Ghoshal, & Kapoor, 2007) because of avoiding estrogenic effect from ovary. For 4.9% inappropriate use in premenopausal, these were found in early stage breast cancer who were prescribed Tamoxifen for 5 years and switched to Letrozole while they still premenopausal. For 0.9% inappropriate use in hormone receptor negative (ER-and PR-), some pathology included ER/PR always be reviewed when the patients referred. Prescribing Letrozole in ER(-)/PR(-) were found.
The breast cancer patients who visited at cancer hospital were under 3 main health benefit schemes; universal coverage scheme (UCS), civil servant medication benefit scheme (CSMBS) and social security scheme (SSS). 7.80% of Thai people are in CSMBS, 15.46% in SSS and 75.70% in UCS (Jindapol N., 2014) . Some study showed trend of inappropriate use and high consume of medication cost in CSMBS (Jindapol N., 2014) . This study aimed to investigate the different in appropriate use of Letrozole in any schemes. Although the appropriate use in UCS was related with the reimbursement condition more than other schemes, but the result showed not significant in appropriate use of Letrozole in different health benefit schemes (p=0.081).
In conclusion, Letrozole has a major role as endocrine therapy in early stage and advanced breast cancer. To evaluated how appropriate use of Letrozole in breast cancer patients, the study showed 13.52% of inappropriate use because of duration, menopausal status and hormone receptor. To prescribe appropriate indication did not referred to the appropriate practice along the treatment. Drug use evaluation was very useful for detecting the sign of inappropriate use and immediately feedback to the stakeholder for developing medication policy in the future. Furthermore there was not significantly different in appropriate use of Letrozole in any health benefit schemes.
Limitations: as the referral cancer hospital, majority of patients were referred and previous treated with Letrozole from other hospital. Some missing clinical data and unaccountable number of Letrozole were excluded as 6.61% (45 from 681 prescriptions). 
